Triple-Negative Metastatic Breast Cancer: Beyond ER, PR, and HER2 - Metastatic Breast Cancer Trial Talk

Research News

Triple-negative breast cancer is defined as being negative for the estrogen receptor, progesterone receptor, and HER2 biomarkers. Because of this, targeted therapies for these biomarkers do not work for triple-negative MBC. As a result, triple-negative MBC is commonly only treated with chemotherapy. However, researchers are beginning to understand that triple-negative MBC expresses other biomarkers that can be treated with targeted therapy.

Read more about targeted therapy, and learn about potential targeted therapies for triple-negative MBC.

Targeted Therapy and Triple-Negative MBC
Target: PD-L1
Target: Trop2
Target: Androgen Receptors
Target: AKT
Metastatic Trial Search: Trials for Triple-Negative MBC Targets

Last Modified on September 26, 2023



for past articles or specific information.